
Developers by Headquarter Region and Therapeutic Approach






Within-graph labels represent headquarter region totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to regional totals
Please see "Methodology Notes" for additional details

Developer Data - 2023 Q1 | 1

Developers by Therapeutic Approach and Headquarter Region





Within-graph labels represent therapeutic approach totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to regional totals
Please see "Methodology Notes" for additional details

Developer Data - 2023 Q1 | 2

Methodology Notes for Developer Data



Methodology Notes

1. Developer data represent a snapshot in time; this snapshot was taken in July 2023.

2. *Developer data consist of the primary owners of a therapeutic drug or platform considered to be part of the durable regenerative medicine sector by ARM. This includes cell, gene, gene-modified cell (GMCT), and tissue engineering therapies.

2a. As durability is a key scoping factor, ARM typically excludes non-durable treatments where possible (antisense-based gene therapies, vaccines). Notable exceptions: Krystal Bio's topical cream, Vyjuvek.

2b. In other reports, ARM typically allocates GMCTs to gene therapy or cell-based immunooncology (CBIO), based on indication. As indication is not present in this dataset, that allocation is not possible here.

3. *Developer headquarter regions are based on the location of the parent headquarters of a company, whenever known, at the highest definition of 'Parent Company' available. For single-entity and/or single-location developers, the company is considered its own parent.

4. Therapeutic developers may have multiple therapeutic approaches in their pipeline and/or portfolio; the sum of therapeutic approach totals may not be equivalent to developer totals.

* Updated in 2023